Avalo Therapeutics AVTX Business Segments — Clinical expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept avtx:ClinicalExpenses.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's business segments — clinical expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's business segments — clinical expenses?
- Avalo Therapeutics (AVTX) reported business segments — clinical expenses of $5.6M in Q1 2026.
- How has Avalo Therapeutics's business segments — clinical expenses changed year-over-year?
- Avalo Therapeutics's business segments — clinical expenses increased by 45.5% year-over-year, from $3.85M to $5.6M.
- What is the long-term trend for Avalo Therapeutics's business segments — clinical expenses?
- Over 2 years (2023 to 2025), Avalo Therapeutics's business segments — clinical expenses has grown at a 107.4% compound annual growth rate (CAGR), from $5.78M to $24.87M.
- What does business segments — clinical expenses mean?
- Includes all costs directly related to conducting human clinical trials, such as patient recruitment, site management, and data collection. These expenses reflect the intensity and scale of the company's efforts to validate drug candidates in human subjects. High clinical expenses are indicative of active, late-stage development programs moving toward potential regulatory submission.